Skip to main content

Year: 2024

Enthusiast Gaming Achieves Profitability, Reports Q3 2024 Financial Results

Reports Positive Adjusted EBITDA and Expanded Gross Margins TORONTO, Nov. 14, 2024 (GLOBE NEWSWIRE) — Enthusiast Gaming Holdings Inc. (“Enthusiast Gaming” or the “Company”) (TSX: EGLX), a leading gaming media and entertainment company, today announced financial results for the three months ended September 30, 2024 (“Q3 2024”). “This quarter marks a transformative milestone for the Company, achieving our first profitable quarter on an Adjusted EBITDA basis,” said Adrian Montgomery, Interim CEO of Enthusiast Gaming. “This accomplishment is a direct result of the strategic refocusing efforts we began in Q1 and our relentless pursuit of operational efficiencies—all achieved without compromising the growth of our communities or the quality of our content. By optimizing our operations, streamlining costs, and prioritizing high-margin...

Continue reading

POET Technologies Reports Third Quarter 2024 Financial Results

Quarter Marks Strong Balance Sheet and Expanded Customer Engagements TORONTO, Nov. 14, 2024 (GLOBE NEWSWIRE) — POET Technologies Inc. (“POET” or the “Company”) (TSX Venture: PTK; NASDAQ: POET), the designer and developer of the POET Optical Interposer™, Photonic Integrated Circuits (PICs) and light sources for the data center, tele-communication and artificial intelligence markets, today reported its unaudited condensed consolidated financial results as at and for the three months ended November 30, 2024. The Company’s financial results as well as the Management’s Discussion and Analysis have been filed on SEDAR. All financial figures are in United States dollars (“USD”) unless otherwise indicated. Management Comments “We are very proud of the progress POET has made this quarter, particularly with strategic partnerships...

Continue reading

Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results

COVID: Phase 1 pharmacokinetic profile supports the potential for ratutrelvir to be dosed as a once-a-day, single drug, 10-day treatment course, without ritonavir, and with a lower likelihood of clinical rebound and good overall tolerability Flu: Phase 1 pharmacokinetic profile supports the potential for tivoxavir marboxil to be a one-time treatment for flu, including pandemic and avian flu, with good overall tolerabilityNEWTOWN, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) — Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for respiratory viral diseases, today outlined recent business updates and reported unaudited financial results for the third quarter ended September 30, 2024. “Traws is making excellent progress with its clinical pipeline. Phase 1 data for...

Continue reading

Sysco Metro New York Donates 2,500 Turkeys to Feed Those in Need This Thanksgiving

The company also donated $10,000 to City HarvestSysco Metro New York at City HarvestSysco Metro New York Donates $10,000 to City HarvestNEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) — Today, Sysco Corporation (NYSE:SYY), the world’s largest food distributor, presented a check for $10,000 to City Harvest, New York’s first and largest food rescue organization, to support the community where Sysco operates. Sysco’s donation is part of the company’s signature Nourishing Neighbors® program where a portion of the proceeds from each Sysco branded case sold in local communities is donated back to charitable organizations in those communities. This is an important time of year for food banks and pantries as they gear up to feed those in need this holiday season. Sysco Metro New York also delivered 2,500 turkeys to City Harvest to be...

Continue reading

Royalty Pharma Announces Inaugural Prize for Impact in Healthcare

Royalty Pharma inaugural Prize for Impact in Healthcare awarded to Michael Milken, the founder of the Milken Institute, Faster Cures & the Prostate Cancer Foundation The Prize includes a charitable donation to further fund medical researchNEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) — Royalty Pharma plc (Nasdaq: RPRX) today announced the inaugural Royalty Pharma Prize for Impact in Healthcare, which honors individuals or organizations who positively impact healthcare, was awarded to Micheal Milken. The prize includes a $250,000 charitable donation to support medical research or educational initiatives that further the recipient’s work. “I am delighted to award the inaugural Royalty Pharma Prize for Impact in Healthcare to Michael Milken,” said Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma. “Mike has...

Continue reading

Precision Optics Reports First Quarter Fiscal Year 2025 Financial Results

Conference Call Scheduled for today, November 14, 2024, at 5:00pm ET. GARDNER, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) — Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, announced operating results on an unaudited basis for its first quarter fiscal year 2025 for the period ended September 30, 2024. Q1 2025 Financial Highlights (3 Months Ended September 30, 2024):Revenue was $4.2 million compared to $4.3 million in the same quarter of the previous fiscal year and in line with the expectations provided in September 2024. Engineering revenue was $1.9 million compared to $1.9 million in the same quarter of the previous fiscal year. Production revenue was $2.3 million compared to $2.4 million in the same quarter of...

Continue reading

Skyline Bankshares, Inc. Announces Third Quarter 2024 Results

FLOYD, Va. and INDEPENDENCE, Va., Nov. 14, 2024 (GLOBE NEWSWIRE) — Skyline Bankshares, Inc. (the “Company”) (OTC QX: SLBK) – the holding company for Skyline National Bank (the “Bank”) – announced its results of operations for the third quarter of 2024.   As previously announced, the Company acquired Johnson County Bank (“JCB”) on September 1, 2024, with the Company as the surviving corporation. For accounting purposes, the Company is considered the acquiror and JCB is considered the acquiree in the transaction. As such, all information contained herein as of and for periods prior to September 1, 2024 reflects the operations of the Company prior to the merger. The Company recorded net income of $1.1 million, or $0.19 per share, for the quarter ended September 30, 2024, compared to net income of $1.8 million, or $0.33 per share,...

Continue reading

Acutus Medical Reports Third Quarter and Year-To-Date 2024 Financial Results

CARLSBAD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (OTC: AFIB) today reported results for the third quarter and year-to-date of 2024. Recent Highlights:Third quarter revenue from Continuing Operations of $5.3 million grew 156% year-over-year, from $2.1 million in the same quarter last year.Operating income for continuing operations was $0.1 million, an improvement of 119% compared to the same period last year.Recorded $2.4 million in gain on sale of business, a decrease of 8% compared to the same period last year.Cash, cash equivalents, marketable securities and restricted cash were $12.6 million as of September 30, 2024.Third Quarter 2024 Financial ResultsRevenue from Continuing Operations was $5.3 million for the third quarter of 2024, an increase of 156% compared to...

Continue reading

LifeWallet Announces Third Quarter 2024 Financial Results

MIAMI, Nov. 14, 2024 (GLOBE NEWSWIRE) — MSP Recovery, Inc. d/b/a LifeWallet (NASDAQ: LIFW) (“LifeWallet,” or the “Company”), a Medicare, Medicaid, commercial, and secondary payer reimbursement recovery and technology leader, today announced financial results for the quarter ended September 30, 2024. LifeWallet Chief Executive Officer, John H. Ruiz, said, “From additional settlements to the processing of additional claims data, we continue to see progress across all lines of business. We’re also reaping the rewards of reduced operating expenses, which have had a positive impact on our financials. In addition to providing invaluable technological resources to patients, providers, payers, and attorneys, our cost-cutting solutions can discover wasted federal funds and recover Medicare reimbursements to preserve tax dollars, benefiting...

Continue reading

Super League Announces Third Quarter 2024 Financial Results

~ Third Quarter Highlighted by Transformative Agreement and Anticipated Strategic Investment from Infinite Reality including Merger of World-Class Audience Assets ~ ~ Q3 Net Loss Per Share Narrows to Improve Operational Efficiency on Continued Reduction in Operating Expenses ~ SANTA MONICA, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) — Super League (Nasdaq: SLE), a leader in redefining the gaming industry as a media channel, today announced that it has released third quarter 2024 financial results in the form of a shareholder letter, which can be accessed under the Quarterly Results section of the Company’s investor relations website. Management Commentary by Chief Executive Officer, Ann Hand: “During the third quarter, while revenue remained relatively flat, we are pleased with our continued march toward profitability illustrated...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.